Oncology

Live Report from ASH:
Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML

Richard Stone
Richard Stone

RICHARD STONE, Dana-Farber Cancer Institute, Boston
GEORGE CANELLOS, Dana-Farber Cancer Institute

New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where does dasatinib stand as an emerging CML therapy? Richard Stone of the Dana-Farber Cancer Institute in Boston explained all to Derek Thorne, while George Canellos, of the same institute, gave another perspective on the data.

Download this interview

Similar Interviews

  • Audio Journal of Oncology - September 1st, 2006">Audio Journal of Oncology - September 1st, 2006
  • Mark Socinski

  • New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura
  • Terry Gernsheimer TERRY GERNSHEIMER, University of Washington Medical Center, Seattle An investigational drug AMG 531 has

  • Audio Journal of Oncology - June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6">Audio Journal of Oncology - June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6
  • Robert Mayer Thierry Facon

    Post a comment

    Subscribe to Audio Medica Podcast